Abstract
The CHRYSALIS study (NCT02609776) is an ongoing Phase 1 trial evaluating the combination of amivantamab (ami) and lazertinib (laz) in patients with epidermal growth factor receptor (EGFR)-mutant (EGFRm) NSCLC. As previously reported, all 20 patients in the treatment-naive cohort who received ami + laz achieved a partial response (overall response rate of 100.0% [95% CI, 83.2-100.0]) after a median follow-up of 7 months (Cho Ann Oncol 2021; 31:S813; 1258O). Herein, we present updated results from this treatment-naive cohort.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call